Trial Profile
Randomized, Double Blind Trial of Bromfenac BID (0.09%) as an Adjunct to Argon Laser Therapy in the Treatment of Diabetic Macular Edema.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 24 Dec 2009
Price :
$35
*
At a glance
- Drugs Bromfenac (Primary)
- Indications Diabetic macular oedema
- Focus Therapeutic Use
- 09 Sep 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 09 Sep 2009 Actual end date (May 2009) added as reported by ClinicalTrials.gov.
- 07 Apr 2009 Planned end date changed from 1 Jan 2009 to 1 Jun 2009 as reported by ClinicalTrials.gov.